Cas:10310-32-4 Tribenoside manufacturer & supplier

We serve Chemical Name:Tribenoside CAS:10310-32-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

Tribenoside

Chemical Name:Tribenoside
CAS.NO:10310-32-4
Synonyms:Tribenosido [INN-Spanish];TBGF;Tribenzoside;Tribenosidum [INN-Latin];Glivenol;ethyl-3,5,6-tri-O-benzyl-D-glucofuranoside;EINECS 233-687-2;tribenoside;Glyvenal;Glyvenol
Molecular Formula:C29H34O6
Molecular Weight:478.57700
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:618.9ºC at 760mmHg
Density:1.19g/cm3
Index of Refraction:1.59
PSA:66.38000
Exact Mass:478.23600
LogP:4.49630

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:


Contact us for information like Tribenosido [INN-Spanish] chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Glyvenol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Tribenosido [INN-Spanish] Use and application,tribenoside technical grade,usp/ep/jp grade.


Related News: At the same time, due to the relatively late development of the bulk drug business in China, most of the established bulk drug companies are currently in the field of commonly used generic drug bulk drugs. Stand up. Tribenoside manufacturer Vietnam recently barred almost all flights to and from mainland China, Hong Kong and Macau until May 1, according to the United States Federal Aviation Administration. Tribenoside supplier Zhejiang Huahai Pharmaceutical: It is a leading company in domestic APIs, especially in the field of cardiovascular drugs. Tribenoside vendor Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037. Tribenoside factory Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037.